ProCE Banner Activity

BCMA-Targeted ADC MEDI2228: First-in-Human Phase I Study in Patients With R/R Multiple Myeloma

Slideset Download
Conference Coverage
In this early study, the anti-BCMA ADC MEDI228 had manageable toxicity with responses seen at all dose levels in patients with heavily pretreated, relapsed/refractory multiple myeloma.

Released: December 14, 2020

Expiration: December 13, 2021

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology